The Durability and Avidity of MPXV-specific Antibodies Induced by the Two-dose MVA-BN Mpox Vaccine

Aaron L. Oom, Angelica C. Kottkamp, Kesi K. Wilson, Miilani Yonatan, Stephanie Rettig, Heekoung Allison Youn, Michael Tuen, Yusra Shah, Ashley L. DuMont, Marie I. Samanovic, Ralf Duerr, Mark J. Mulligan the NYC OSMI Study Group
doi: https://doi.org/10.1101/2024.01.28.24301893

Article Information

doi 
https://doi.org/10.1101/2024.01.28.24301893
History 
  • January 29, 2024.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Aaron L. Oom1,*,*,
  2. Angelica C. Kottkamp1,*,
  3. Kesi K. Wilson1,
  4. Miilani Yonatan1,
  5. Stephanie Rettig1,
  6. Heekoung Allison Youn1,
  7. Michael Tuen1,
  8. Yusra Shah1,
  9. Ashley L. DuMont1,
  10. Marie I. Samanovic1,
  11. Ralf Duerr1,
  12. Mark J. Mulligan1 and
  13. the NYC OSMI Study Group
  1. 1New York University Langone Vaccine Center, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA
  1. ↵*Corresponding author; email: aaron.oom{at}nyulangone.org

  1. ↵* These authors contributed equally

Back to top
Posted January 29, 2024.
Download PDF

Supplementary Material

Data/Code
Email
The Durability and Avidity of MPXV-specific Antibodies Induced by the Two-dose MVA-BN Mpox Vaccine
Aaron L. Oom, Angelica C. Kottkamp, Kesi K. Wilson, Miilani Yonatan, Stephanie Rettig, Heekoung Allison Youn, Michael Tuen, Yusra Shah, Ashley L. DuMont, Marie I. Samanovic, Ralf Duerr, Mark J. Mulligan
medRxiv 2024.01.28.24301893; doi: https://doi.org/10.1101/2024.01.28.24301893
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area